Nkarta, Inc.

Nkarta, Inc. announced it will host a webcast on November 9, 2026, to discuss initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis. The data will be presented at the American College of Rheumatology (ACR) Convergence 2026. The Ntrust trials are multi-center, open-label studies assessing the safety and potential for durable remission of NKX019 in patients with autoimmune diseases.

Nkarta, Inc. reported a significant increase in net loss for the second quarter of 2026, reaching $40.37 million, compared to $22.98 million in the prior year. This was primarily driven by a substantial rise in research and development and general and administrative expenses. The company also recorded impairment charges totaling $8.05 million related to property and equipment and right-of-use assets. Despite current liquidity, management anticipates needing additional capital to fund ongoing research and development activities.

Nkarta, Inc. reported a net loss of $40.4 million, or $0.54 per share, for the second quarter ended June 30, 2026. The company maintained a cash balance of $243.2 million, which is projected to fund operations into 2029. Nkarta also provided updates on its NKX019 clinical program, including continued patient enrollment in Ntrust-1 and Ntrust-2 trials for autoimmune diseases, the initiation of outpatient dosing, and the expectation to present initial clinical data at a medical conference in 2026.

Nkarta, Inc., a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Nkarta President Nadir Mahmood will host a fireside chat on June 30th at 2 p.m. ET to provide updates on the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. A live webcast and replay will be available on the company's investor relations website.

Nkarta, Inc. held its 2026 annual meeting of stockholders on June 10, 2026, where several key matters were submitted to a vote. Stockholders elected two Class III directors, Ali Behbahani and Zachary Scheiner, to serve until the 2029 annual meeting. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 was ratified. Stockholders also provided advisory approval for the compensation paid to named executive officers and voted on the frequency of future advisory votes on executive compensation, with the company determining to hold them annually.

Nkarta, Inc. reported a narrower net loss of $27.8 million for the first quarter of 2026, an improvement from the $32.0 million loss in the same period last year, primarily driven by a significant reduction in general and administrative expenses. The company's total operating expenses decreased to $30.9 million. However, cash and cash equivalents, along with total current assets, saw a decline compared to the end of 2025, and the accumulated deficit grew to $676.1 million.

Nkarta, Inc. reported its first quarter 2026 financial results and significant corporate highlights. The company reached a regulatory agreement with the FDA to amend its protocol, allowing outpatient dosing in community settings, re-dosing, removal of overnight monitoring, and expansion of the Ntrust-2 study to include rheumatoid arthritis patients. Enrollment continues in Ntrust-1 and Ntrust-2, with initial clinical data expected in 2026. Nkarta ended the quarter with $266.7 million in cash, cash equivalents, and investments, which is projected to fund operations into 2029, while reporting a net loss of $27.8 million for the quarter.

Nkarta reported a net loss of $27.8 million for the first quarter of 2026. The company announced a significant regulatory agreement with the FDA to amend its protocol, allowing outpatient dosing in community settings for its NKX019 clinical trials (Ntrust-1 and Ntrust-2), along with re-dosing options and the removal of overnight monitoring. Enrollment is ongoing at the 4 billion cell dose level across all indications, and initial clinical data is expected to be presented at a medical meeting in 2026. Nkarta's cash balance of $266.7 million as of March 31, 2026, is projected to fund operations into 2029.

Nkarta, Inc. announced an agreement with the FDA on key changes to its Ntrust-1 and Ntrust-2 clinical trials for NKX019, an investigational CAR-NK cell therapy for autoimmune diseases. The amendments will enable outpatient administration, significantly reducing patient burden by cutting monitoring time from 24 hours to 2 hours, and expanding access to community research centers. Additionally, the company gained flexibility to re-dose patients in both studies and will add a rheumatoid arthritis cohort to Ntrust-2, broadening the trial's scope.